What is holding up the Unified Patent Court?
A form of unified patent protection has been available in Europe since the 1970s, but enforcement remains purely a national matter. After many years' negotiation, an agreement was signed in February 2013 to create a pan-European court (the UPC), potentially affecting global litigation strategie...
Gespeichert in:
| Veröffentlicht in: | Pharmaceutical patent analyst 2018-09, Vol.7 (5), p.187-192 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 192 |
|---|---|
| container_issue | 5 |
| container_start_page | 187 |
| container_title | Pharmaceutical patent analyst |
| container_volume | 7 |
| creator | Cohen, Liz Johnson, Alan |
| description | A form of unified patent protection has been available in Europe since the 1970s, but enforcement remains purely a national matter. After many years' negotiation, an agreement was signed in February 2013 to create a pan-European court (the UPC), potentially affecting global litigation strategies. A constitutional complaint brought in Germany in 2017 has delayed the project and potentially presents an existential challenge, but more likely the issue is how much further delay it will cause. It remains entirely possible the UPC will start in Q1 2019 (before Brexit). In addition, for patentees such as pharmaceutical companies requiring broad geographic protection, another part of the new system, the unitary patent, would also mean a dramatic reduction in patent maintenance costs. |
| doi_str_mv | 10.4155/ppa-2018-0018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2087996169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216551022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c327t-748757e18cf0ffed38b0041c890e3f1acfe615d97b675d2180f6399adefdcdcd3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMottQevcqCFw-uJtnN10mk-AUFPVg8hm0ysSnt7rrJHvz3pmztQZDAZAaevEwehM4JvikJY7dtW-UUE5njVI7QmOKS51JxenzoWTlC0xDWOCGECqnkKRoVmGDCmRij649VFTMfslWzsb7-zPo2iyvIFrV3Hmz2VkWoYzZr-i7enaETV20CTPf3BC0eH95nz_n89elldj_PTUFFzEUpBRNApHHYObCFXGJcEiMVhsKRyjjghFklllwwS4nEjhdKVRacNekUE3Q15LZd89VDiHrrg4HNpqqh6YOmWAqlOOEqoZd_0HVatU7baUrTFxnBlCYqHyjTNSF04HTb-W3VfWuC9c6kTib1zqTemUz8xT61X27BHuhfbwlQA-D62HcQjIfagB6m9MIbX8M_4T9TZX-t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216551022</pqid></control><display><type>article</type><title>What is holding up the Unified Patent Court?</title><source>PubMed Central</source><creator>Cohen, Liz ; Johnson, Alan</creator><creatorcontrib>Cohen, Liz ; Johnson, Alan</creatorcontrib><description>A form of unified patent protection has been available in Europe since the 1970s, but enforcement remains purely a national matter. After many years' negotiation, an agreement was signed in February 2013 to create a pan-European court (the UPC), potentially affecting global litigation strategies. A constitutional complaint brought in Germany in 2017 has delayed the project and potentially presents an existential challenge, but more likely the issue is how much further delay it will cause. It remains entirely possible the UPC will start in Q1 2019 (before Brexit). In addition, for patentees such as pharmaceutical companies requiring broad geographic protection, another part of the new system, the unitary patent, would also mean a dramatic reduction in patent maintenance costs.</description><identifier>ISSN: 2046-8954</identifier><identifier>EISSN: 2046-8962</identifier><identifier>DOI: 10.4155/ppa-2018-0018</identifier><identifier>PMID: 30101657</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Agreements ; Cooperation ; Councils ; Jurisdiction ; Litigation ; Pharmaceuticals ; Regulation</subject><ispartof>Pharmaceutical patent analyst, 2018-09, Vol.7 (5), p.187-192</ispartof><rights>2018 Newlands Press</rights><rights>Copyright Newlands Press Sep 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c327t-748757e18cf0ffed38b0041c890e3f1acfe615d97b675d2180f6399adefdcdcd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30101657$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Liz</creatorcontrib><creatorcontrib>Johnson, Alan</creatorcontrib><title>What is holding up the Unified Patent Court?</title><title>Pharmaceutical patent analyst</title><addtitle>Pharm Pat Anal</addtitle><description>A form of unified patent protection has been available in Europe since the 1970s, but enforcement remains purely a national matter. After many years' negotiation, an agreement was signed in February 2013 to create a pan-European court (the UPC), potentially affecting global litigation strategies. A constitutional complaint brought in Germany in 2017 has delayed the project and potentially presents an existential challenge, but more likely the issue is how much further delay it will cause. It remains entirely possible the UPC will start in Q1 2019 (before Brexit). In addition, for patentees such as pharmaceutical companies requiring broad geographic protection, another part of the new system, the unitary patent, would also mean a dramatic reduction in patent maintenance costs.</description><subject>Agreements</subject><subject>Cooperation</subject><subject>Councils</subject><subject>Jurisdiction</subject><subject>Litigation</subject><subject>Pharmaceuticals</subject><subject>Regulation</subject><issn>2046-8954</issn><issn>2046-8962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMottQevcqCFw-uJtnN10mk-AUFPVg8hm0ysSnt7rrJHvz3pmztQZDAZAaevEwehM4JvikJY7dtW-UUE5njVI7QmOKS51JxenzoWTlC0xDWOCGECqnkKRoVmGDCmRij649VFTMfslWzsb7-zPo2iyvIFrV3Hmz2VkWoYzZr-i7enaETV20CTPf3BC0eH95nz_n89elldj_PTUFFzEUpBRNApHHYObCFXGJcEiMVhsKRyjjghFklllwwS4nEjhdKVRacNekUE3Q15LZd89VDiHrrg4HNpqqh6YOmWAqlOOEqoZd_0HVatU7baUrTFxnBlCYqHyjTNSF04HTb-W3VfWuC9c6kTib1zqTemUz8xT61X27BHuhfbwlQA-D62HcQjIfagB6m9MIbX8M_4T9TZX-t</recordid><startdate>20180901</startdate><enddate>20180901</enddate><creator>Cohen, Liz</creator><creator>Johnson, Alan</creator><general>Future Science Ltd</general><general>Newlands Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180901</creationdate><title>What is holding up the Unified Patent Court?</title><author>Cohen, Liz ; Johnson, Alan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c327t-748757e18cf0ffed38b0041c890e3f1acfe615d97b675d2180f6399adefdcdcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Agreements</topic><topic>Cooperation</topic><topic>Councils</topic><topic>Jurisdiction</topic><topic>Litigation</topic><topic>Pharmaceuticals</topic><topic>Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Liz</creatorcontrib><creatorcontrib>Johnson, Alan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical patent analyst</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Liz</au><au>Johnson, Alan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What is holding up the Unified Patent Court?</atitle><jtitle>Pharmaceutical patent analyst</jtitle><addtitle>Pharm Pat Anal</addtitle><date>2018-09-01</date><risdate>2018</risdate><volume>7</volume><issue>5</issue><spage>187</spage><epage>192</epage><pages>187-192</pages><issn>2046-8954</issn><eissn>2046-8962</eissn><abstract>A form of unified patent protection has been available in Europe since the 1970s, but enforcement remains purely a national matter. After many years' negotiation, an agreement was signed in February 2013 to create a pan-European court (the UPC), potentially affecting global litigation strategies. A constitutional complaint brought in Germany in 2017 has delayed the project and potentially presents an existential challenge, but more likely the issue is how much further delay it will cause. It remains entirely possible the UPC will start in Q1 2019 (before Brexit). In addition, for patentees such as pharmaceutical companies requiring broad geographic protection, another part of the new system, the unitary patent, would also mean a dramatic reduction in patent maintenance costs.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>30101657</pmid><doi>10.4155/ppa-2018-0018</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2046-8954 |
| ispartof | Pharmaceutical patent analyst, 2018-09, Vol.7 (5), p.187-192 |
| issn | 2046-8954 2046-8962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2087996169 |
| source | PubMed Central |
| subjects | Agreements Cooperation Councils Jurisdiction Litigation Pharmaceuticals Regulation |
| title | What is holding up the Unified Patent Court? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A11%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%20is%20holding%20up%20the%20Unified%20Patent%20Court?&rft.jtitle=Pharmaceutical%20patent%20analyst&rft.au=Cohen,%20Liz&rft.date=2018-09-01&rft.volume=7&rft.issue=5&rft.spage=187&rft.epage=192&rft.pages=187-192&rft.issn=2046-8954&rft.eissn=2046-8962&rft_id=info:doi/10.4155/ppa-2018-0018&rft_dat=%3Cproquest_cross%3E2216551022%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216551022&rft_id=info:pmid/30101657&rfr_iscdi=true |